Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020
08:30pm, Monday, 11'th May 2020
In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headqua
Cellectis SA (CLLS) Q1 2020 Earnings Call Transcript
06:00pm, Saturday, 09'th May 2020
CLLS earnings call for the period ending March 31, 2020.
Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
10:00am, Friday, 08'th May 2020
Cellectis S.A. (EPA:ALCLS) just released its quarterly report and things are looking bullish. The results were...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020
08:30pm, Wednesday, 06'th May 2020
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM.
Gilead, Takeda Rumored to Have Sights on Iovance
10:13pm, Thursday, 30'th Apr 2020
Potential suitors looking to expand their work in cancer likely covet company's technology Continue reading...
Gilead, Takeda Rumored to Have Sights on Iovance
09:24pm, Thursday, 30'th Apr 2020
Gilead, Takeda Rumored to Have Sights on Iovance, Stocks: IOVA,GILD,TAK,CLLS, release date:Apr 30, 2020
Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT
08:30pm, Wednesday, 29'th Apr 2020
NEW YORK, April 29, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
Bio Roundup: Alnylam's Billions, COVID-19 Vaccines, Moma Debuts & More
01:28pm, Friday, 17'th Apr 2020
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn't the only way for biotech companies to
Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis
09:38pm, Monday, 13'th Apr 2020
Cellectis (NASDAQ: ]) has appointed Carrie Brownstein to serve as its chief medical officer. She worked most recently at Celgene as vice president of
Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer
08:30pm, Monday, 13'th Apr 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced
Allogene Therapeutics: Revisiting Its Prospects 5 Months On
07:24am, Monday, 30'th Mar 2020
Since my last article on Allogene Therapeutics about 5 months ago, its share price has fallen by around 30%. I was bearish on the company’s short-term prospects
Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
02:02pm, Wednesday, 25'th Mar 2020
Sangamo has announced several impressive partnerships with global biotech and big pharma companies. Its recent deal with Biogen gives it ~$700M cash on hand, at
Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors
04:38am, Friday, 20'th Mar 2020
Since my last article on Iovance Biotherapeutics about 4 months, its share price went up by more than 75% on buyout rumors, before crashing back down with the C
BTIG's stocks for the storm
09:30pm, Sunday, 15'th Mar 2020
News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
Head-To-Head Survey: Autolus Therapeutics (NASDAQ:AUTL) & Iovance Biotherapeutics (NASDAQ:IOVA)
06:34am, Friday, 13'th Mar 2020
Autolus Therapeutics (NASDAQ:AUTL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of
